卡瑞利珠单抗和化疗联合阿帕替尼救治性治疗复发或晚期头颈鳞癌的疗效分析  

Efficacy of camrelizumab and chemotherapy plus apatinib in recurrent or advanced head and neck squamous cell carcinoma

作　　者：魏景健[1] 牛倩倩 张爱侠[1] 韩琨[1] 李晓东 郑浩[1] 孟箭[1] WEI Jingjian;NIU Qianqian;ZHANG Aixia;HAN Kun;LI Xiaodong;ZHENG Hao;MENG Jian(Department of Stomatology,Xuzhou Central Hospital,Xuzhou,Jiangsu 221009,China;Department of Stomatology,Pingyi County Hospital of Traditional Chinese Medicine,Linyi,Shandong 273300,China)

机构地区：[1]徐州市中心医院口腔科,江苏徐州221009 [2]平邑县中医医院口腔科,山东临沂273300

出　　处：《安徽医药》2025年第1期174-177,I0006,共5页Anhui Medical and Pharmaceutical Journal

基　　金：国家口腔疾病临床医学研究中心开放课题项目(NCRCO-202101);徐州市科技项目(KC23172)。

摘　　要：目的观察卡瑞利珠单抗和化疗联合阿帕替尼救治性治疗复发或晚期头颈鳞癌(HNSCC)的疗效及安全性。方法回顾性分析2020年3月至2021年11月徐州市中心医院口腔科收治的8例复发或晚期HNSCC病人,予卡瑞利珠单抗和化疗行2周期治疗后,待瘤体缩小,卡瑞利珠单抗和阿帕替尼维持性治疗;主要观察指标为疾病控制率(DCR)和客观缓解率(ORR),次要观察指标为总生存期(OS)、无进展生存时间(PFS)和不良反应发生率。结果纳入8例复发/晚期HNSCC病人中,ORR为62.5%(5/8),DCR为87.5%(7/8)。随访时间为1~32个月,中位OS为18个月,中位PFS未达到,不良反应发生率为100%,但程度较轻。结论卡瑞利珠单抗和化疗联合阿帕替尼治疗复发或晚期HNSCC病人具有较好的疗效,能够有效控制疾病进展,提高病人生存质量。Objective To observe the efficacy and safety of camrelizumab and chemotherapy plus apatinib in the salvageable treatment of recurrent or advanced head and neck squamous cell carcinoma(HNSCC).Methods Eight patients with recurrent or advanced HNSCC admitted to the Department of Stomatology of Xuzhou Central Hospital from March 2020 to November 2021 were retrospectively analyzed.After two cycles of treatment with camrelizumab and chemotherapy,camrelizumab and apatinib were used as maintenance treatment after tumor shrinkage.The main observation indexes were disease control rate(DCR)and objective remission rate(ORR),and the secondary observation indexes were overall survival time(OS),progression free survival time(PFS)and incidence of adverse reactions.Results Among 8 patients with recurrent or advanced HNSCC,ORR was 62.5%(5/8)and DCR was 87.5%(7/8).The follow-up time was 1-32 months,the median OS was 18 months,the median PFS was not reached,and the incidence of adverse reactions was 100%,but the degree was mild.Conclusion Camrelizumab and chemotherapy plus apatinib has good efficacy in the treatment of recurrent or advanced HNSCC patients,which can effectively control disease progression and improve patients´quality of life.

关 键 词：头颈部肿瘤 癌 鳞状细胞 卡瑞利珠单抗 阿帕替尼 免疫治疗 化疗 

分 类 号：R739.91[医药卫生—肿瘤]